Registries

RESPONSE is designed to assess the long-term safety profile of RAPTIVA [efalizumab], in patients with chronic moderate to severe plaque psoriasis who are candidates for treatment with RAPTIVA.

For more information regarding this registry, please call the RESPONSE Registry Hotline at 1-800-516-1505.

If you have a patient who is pregnant and has been treated with RAPTIVA [efalizumab], please contact FOLLOW, the RAPTIVA Pregnancy Registry Study, at 1-877-RAPTIVA (1-877-727-8482) and select option 3.